Composition
Inj 200 mg: Dacarbazine 200 mg (as citrate), mannitol 75 mg; vial.
Indications & Dosage
Metastatic melanoma and malignant lymphomas, Testicular tumours, colorectal cancers, tumours of GIT, CNS, soft tissues, Hodgkins disease: BY IV INF, OR BY IV INJ: Adult: 200-500 mg/m2. Refer individual protocol.
Administration
Infuse over 30-60 min; rapid infusion may cause severe venous irritation. Reconstitute with a minimum of 2 ml (100 mg vial) or 4 ml (200 mg vial) of SWFI, D5W, or NS. Dilute to a concentration of 10 mg/ml. Standard IV dilution: 250-500 ml D5W or NS.
Compatibility
Stable in NS, SWFI.
Stability
Reconstituted solution is stable for 24 hours at room .temperature (20C) and 96 hours under refrigeration (4C). Solutions for infusion (in D5W or NS) are stable for 24 hours at room temperature and protected from light. Decomposed drug turns pink.
Interactions
BCG, clozapine, natalizumab, pimecrolimus, tacrolimus (topical), live vaccines (avoid), abiraterone acetate, CYP1A2 inhibitors, CYP2E1 inhibitors, deferasirc. denosumab, MAO inhibitors, roflumilast, trastuzumab.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding
Side Effects
Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, myelosuppression, oral mucositis, severe nausea, severe vomiting, tumourlysis syndrome, vomiting. Rare: liver necrosis due to hepatic vein thrombosis